Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Acute Kidney Injury (1)
- Adult (1)
- Adverse drug effects (1)
- Aged (1)
- Alzheimer (1)
-
- Anti-Bacterial Agents (1)
- Beta-lactams (1)
- Bladder antimuscarinics (1)
- Cefepime (1)
- Cephalosporins (1)
- Cholinergic (1)
- Clinical therapeutics (1)
- Cognitive function (1)
- Female (1)
- Humans (1)
- Kidney (1)
- Male (1)
- Middle Aged (1)
- Multidrug resistance (1)
- Multivariate Analysis (1)
- National Alzheimer's Coordinating Center (1)
- Nephrotoxicity (1)
- Penicillanic Acid (1)
- Pharmacokinetics (1)
- Pharmacology (1)
- Piperacillin (1)
- Piperacillin-tazobactam (1)
- Retrospective Studies (1)
- Toxicity (1)
- Vancomycin (1)
Articles 1 - 3 of 3
Full-Text Articles in Life Sciences
Nephrotoxicity In Patients With Or Without Cystic Fibrosis Treated With Polymyxin B Compared To Colistin, Ryan L. Crass, Wilbur Cliff Rutter, Donna R. Burgess, Craig A. Martin, David S. Burgess
Nephrotoxicity In Patients With Or Without Cystic Fibrosis Treated With Polymyxin B Compared To Colistin, Ryan L. Crass, Wilbur Cliff Rutter, Donna R. Burgess, Craig A. Martin, David S. Burgess
Pharmacy Practice and Science Faculty Publications
Nephrotoxicity is the primary adverse effect of the polymyxins. The relative rates of toxicity of polymyxin B and colistin have not been fully elucidated, especially in patients with cystic fibrosis (CF). A retrospective cohort study of adults treated with polymyxin B or colistin for at least 48 h was conducted. The primary endpoint was the incidence of kidney injury assessed by RIFLE (i.e., risk, injury, failure, loss, end-stage renal disease) criteria. Risk factors for kidney injury were evaluated using multivariate Cox regression. A total of 414 patients were evaluated, 220 of whom had CF. In patients without CF, there was …
Nephrotoxicity During Vancomycin Therapy In Combination With Piperacillin-Tazobactam Or Cefepime, Wilbur Cliff Rutter, Jessica N. Cox, Craig A. Martin, Donna R. Burgess, David S. Burgess
Nephrotoxicity During Vancomycin Therapy In Combination With Piperacillin-Tazobactam Or Cefepime, Wilbur Cliff Rutter, Jessica N. Cox, Craig A. Martin, Donna R. Burgess, David S. Burgess
Pharmacy Practice and Science Faculty Publications
Recent reports have demonstrated that vancomycin (VAN) may lead to an increase in the incidence of acute kidney injury (AKI) when it is combined with antipseudomonal beta-lactams. This study compared the incidence of AKI associated with VAN plus piperacillin-tazobactam (TZP) or cefepime (FEP). This was a retrospective, matched cohort study that was conducted at an academic medical center between September 2010 and September 2014 and that included adult patients without severe chronic or structural kidney disease, dialysis, pregnancy, cystic fibrosis, or a hospital transfer receiving TZP-VAN or FEP-VAN for at least 48 h. The primary outcome was the difference in …
Bladder Antimuscarinics And Cognitive Decline In Elderly Patients, Daniela Claudia Moga, Erin L. Abner, Qishan Wu, Gregory A. Jicha
Bladder Antimuscarinics And Cognitive Decline In Elderly Patients, Daniela Claudia Moga, Erin L. Abner, Qishan Wu, Gregory A. Jicha
Pharmacy Practice and Science Faculty Publications
Introduction: The evidence on the impact of bladder antimuscarinics initiation on cognitive function in older adults is inconsistent.
Methods: A retrospective analysis of data from the National Alzheimer's Coordinating Center (NACC) on enrollees 65 years and older evaluated the association between antimuscarinic initiation and cognitive decline. We defined decline from baseline (yes/no) for cognitive assessments included in the NACC Uniform Data Set 2.0 battery. New users were matched on year of enrollment and time in the cohort to randomly selected nonusers. Analyses were conducted using inverse probability of treatment weights based on baseline propensity scores.
Results: Our analyses included 698 …